8-K: Xtant Medical Reports 12% Revenue Growth in Third Quarter, Reaffirms Full Year Guidance

Xtant Medical announced a 12% increase in third-quarter revenue and reaffirmed its full-year revenue guidance of $116 million to $120 million.

Summary

• Xtant Medical reported a 12% increase in revenue for the third quarter of 2024, reaching $27.9 million, compared to $25.0 million in the same quarter of the previous year.
• Year-to-date revenue stands at $85.8 million, a 36% increase compared to the prior year period.
• The company's gross margin was 58.4% for the quarter, down from 61.3% in the prior year quarter.
• Xtant Medical experienced a net loss of $5.0 million in the third quarter of 2024, compared to a net income of $9.2 million in the same quarter of the previous year, which included an $11.0 million bargain purchase gain.
• Adjusted EBITDA for the third quarter was a loss of $196,000, compared to a profit of $440,000 in the prior year quarter.
• The company reaffirmed its full-year 2024 revenue guidance of $116 million to $120 million, representing a 27% to 31% annual growth.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the revenue growth and reaffirmed guidance, but tempered by the net loss and decreased gross margin. The company is showing growth but needs to improve profitability.

Positives

• The company achieved a 12% increase in revenue for the third quarter of 2024.
• Year-to-date revenue has increased by 36% compared to the same period last year.
• The launch of OsteoVive+ is expected to improve margins due to internal production.
• The company has reaffirmed its full-year revenue guidance, indicating confidence in future performance.
• The company has secured a minimum of $5.25 million in licensing and royalty fees from a new agreement.
• The company completed a $5.0 million private placement.

Negatives

• The company experienced a net loss of $5.0 million in the third quarter of 2024.
• Gross margin decreased to 58.4% from 61.3% in the prior year quarter.
• Adjusted EBITDA was a loss of $196,000 for the quarter, compared to a profit of $440,000 in the prior year quarter.
• Operating expenses increased by 7.3% compared to the same quarter last year.

Risks

• The company's future operating results and financial performance are subject to risks.
• There are risks associated with the company's acquisitions and the integration of those businesses.
• Anticipated shortages of stem cells could adversely affect future revenues.
• The company faces risks related to competition, innovation, and product development.
• The company is dependent on key independent agents for a significant portion of its revenue.
• Labor and hospital staffing shortages could affect the company's business.
• Inflation, increased interest rates, and supply chain disruptions pose risks.
• The company is subject to product liability claims and other litigation.
• The company's ability to service debt and maintain sufficient liquidity is a risk.
• The company's ability to obtain and maintain regulatory approvals is a risk.

Future Outlook

Xtant Medical reaffirmed its full-year 2024 revenue guidance of $116 million to $120 million, representing a 27% to 31% annual growth. The company expects growth in the fourth quarter to be driven by the strength of its products and continued strong operational execution.

Management Comments

• Sean Browne, President and CEO of Xtant Medical, stated, 'During the third quarter, we expanded our market opportunities with the launch of two new products, OsteoVive+ and Cortera Posterior Fixation System.'
• Sean Browne also stated, '2024 is shaping up largely as we planned with revenue growth of 36% year-to-date. We are therefore reaffirming our full year revenue guidance of $116 million to $120 million.'

Industry Context

The company operates in the global medical technology sector, focusing on surgical solutions for spinal disorders. The launch of new products and the expansion of market opportunities align with industry trends of innovation and growth in the orthobiologics and spinal implant markets. The company's focus on organic growth and internal production of key products like OsteoVive+ is a strategic move to improve profitability and control the supply chain.

Comparison to Industry Standards

• While Xtant Medical's revenue growth of 12% in the third quarter is positive, it is important to compare this to the growth rates of its competitors in the spinal implant and orthobiologics market. Companies like Medtronic and Stryker, which are larger players, often report single-digit growth rates, but their scale is much larger.
• The decrease in gross margin from 61.3% to 58.4% is a point of concern and should be compared to the gross margins of similar-sized companies in the sector. Companies like NuVasive and Globus Medical typically maintain higher gross margins, indicating potential areas for Xtant to improve efficiency.
• The adjusted EBITDA loss of $196,000 compared to a profit of $440,000 in the prior year quarter is a significant swing and needs to be benchmarked against the profitability of peers. Companies in the growth phase often prioritize revenue growth over immediate profitability, but consistent losses can be a concern for investors.
• The reaffirmation of full-year revenue guidance of $116 million to $120 million is a positive sign, but the company's ability to achieve this target will depend on its performance in the fourth quarter. This guidance should be compared to the growth expectations of other companies in the sector to assess its competitiveness.

Stakeholder Impact

• Shareholders will be impacted by the revenue growth and reaffirmed guidance, but also by the net loss and decreased gross margin.
• Employees may be impacted by the company's growth and expansion plans.
• Customers will benefit from the new product launches and expanded offerings.
• Suppliers may be impacted by the company's focus on internal production and supply chain management.
• Creditors will be impacted by the company's financial performance and ability to service debt.

Next Steps

• The company will host a webcast and conference call to discuss the third quarter 2024 financial results on November 12, 2024.
• The company will focus on achieving its full-year revenue guidance of $116 million to $120 million.
• The company will continue to expand its market opportunities with new product launches.

Key Dates

Keywords

Xtant Medical, revenue growth, spinal disorders, orthobiologics, surgical solutions, EBITDA, financial results, medical technology, osteovive, Cortera Posterior Fixation System